Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages 841-849

  Beuschlein, Felix ^a   Weigel, Jens ^b   Saeger, Wolfgang ^c   Kroiss, Matthias ^b   Wild, Vanessa ^d   Daffara, Fulvia ^e   Libé, Rosella ^f   Ardito, Arianna ^e   Ghuzlan, Abir Al ^g   Quinkler, Marcus ^h   Oßwald, Andrea ^a   Ronchi, Cristina L ^b   De Krijger, Ronald ⁱ   Feelders, Richard A ^r   Waldmann, Jens ^j   Willenberg, Holger S ^k   Deutschbein, Timo ^b   Stell, Anthony ^r   Reincke, Martin ^a   Papotti, Mauro ^e   Baudin, Eric ^g   Tissier, Frédérique ^l,m   Haak, Harm R ⁿ   Loli, Paola ^o   Terzolo, Massimo ^e   Allolio, Bruno ^b   Müller, Hans Helge ^p   Fassnacht, Martin ^a,b,q   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF TURIN   (Italy)

^f Institut Cochin   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY HOSPITAL MARBURG   (Germany)

^k HEINRICH HEINE UNIVERSITY   (Germany)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m INSTITUT COCHIN   (France)

ⁿ MÁXIMA MEDICAL CENTER   (Netherlands)

^o OSPEDALE NIGUARDA CA GRANDA   (Italy)

^p UNIVERSITY OF MUNICH   (Germany)

^q UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; GERMAN (CITIZEN); HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR THROMBUS; TUMOR VOLUME; VERY ELDERLY; ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; INFANT; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; KI-67 ANTIGEN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84924955633     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3182     Document Type: Article

References (36)

1. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650-2655.
2. Berruti A, Baudin E, Gelderblom H, et al. Group EGW 2012 Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012(Suppl 7):vii131-138.
3. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12:667-680.
4. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551-4564.
5. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189-2197.
6. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: Surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58:609-615.
7. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152:1150-1157.
8. Porpiglia F, Miller BS, Manfredi M, Fiori C, Doherty GM. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer. 2011;2:372-377.
9. Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol (Oxf). 2010;73:561-565.
10. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-2380.
11. Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98:161-171.
12. Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. 2008;15:1043-1053.
13. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27:4619-4629.
14. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol. 2011;75:585-591.
15. Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501-4504.
16. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1477-1484.
17. Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:192-197.
18. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a revised TNM classification. Cancer. 2009;115:243-250.
19. Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95:4925-4932.
20. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: Analysis of 3851 patients. Ann Surg. 2008;247:490-500.
21. Kutikov A, Mallin K, Canter D, Wong YN, Uzzo RG. Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: Analysis of the National Cancer Database. J Urol. 2011;186:805-810.
22. Assie G, Letouze E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607-612.
23. Volante M, Terzolo M, Fassnacht M, et al. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clin Cancer Res. 2012;18:3452-3461.
24. Ronchi CL, Sbiera S, Kraus L, et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer. 2009;16:907-918.
25. Miller BS, Gauger PG, Hammer GD, Giordano TJ, Doherty GM. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg. 2010;395:955-961.
26. Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation. Eur J Cancer. 2010;46:713-719.
27. Johanssen S, Hahner S, Saeger W, et al. Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int. 2010;107:885-891.
28. McNicol AM, Struthers AL, Nolan CE, Hermans J, Haak HR. Proliferation in adrenocortical tumors: Correlation with clinical outcome and p53 status. Endocr Pathol. 1997;8:29-36.
29. Terzolo M, Boccuzzi A, Bovio S, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology. 2001;57:176-182.
30. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol. 2006;17:345-354.
31. Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008;55:49-55.
32. Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: A clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26:1612-1619.
33. Papotti M, Libè R, Duregon E, Volante M, Bertherat J, Tissier F. The Weiss score and beyond-histopathology for adrenocortical carcinoma. Horm Cancer. 2011;2:333-340.
34. Berruti A, Fassnacht M, Haak H, et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65:832-838.
35. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 2013;169:891-899.
36. Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455-461.